You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PCSK9i

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

STEMI, Dyslipidemias Trial (Evolocumab)

Not yet recruiting
  • STEMI
  • Dyslipidemias
  • (no location specified)
Oct 12, 2022

PCSK9 Inhibitor in Patients With Acute Ischemic Stroke

Not yet recruiting
  • Acute Ischemic Stroke
  • (no location specified)
Nov 14, 2023

Malignant Glioma, Glioblastoma Trial in Durham (Evolocumab)

Recruiting
  • Malignant Glioma
  • Glioblastoma
  • Durham, North Carolina
    Duke University Medical Center
Oct 13, 2022

Molecular Mechanisms and Carotid Atherosclerosis

Completed
  • Diabetes Mellitus, Type 2
  • +2 more
  • statin Oral Tablet plus PCSK9i
  • Naples, Italy
    Raffaele Marfella
Aug 1, 2022

Hemodialysis Access Failure Trial in Shanghai (pcsk9 inhibitor)

Recruiting
  • Hemodialysis Access Failure
  • pcsk9 inhibitor
  • Shanghai, Pudong, China
    Yuanyuan Xie
Sep 10, 2023

Advanced Cancer Trial in Zhengzhou (JS001(Toripalimab)+JS002)

Recruiting
  • Advanced Cancer
  • Zhengzhou, Henan, China
    Henan Tumor Hospital
Jan 10, 2022

Prospective German Very High Cardiovascular Risk Patients

Recruiting
  • Dyslipoproteinemias
  • PCSK9 Inhibitor [EPC]
  • Standard lipid lowering therapy
  • Dresden, Germany
    Medizinische Klinik und Poliklinik III
Mar 18, 2022

Cognitive Function in Patients Treated With PCSK9 Inhibitors

Completed
  • Cognitive Function
  • +2 more
  • PCSK9 inhibitor
  • Cee, A Coruña, Spain
  • +11 more
Jan 13, 2023

NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Alirocumab and Cemiplimab
  • (no location specified)
Jan 31, 2023

Acute Metabolic Effects of Evolocumab and Atorvastatin Trial (Evolocumab)

Not yet recruiting
  • Acute Metabolic Effects of Evolocumab and Atorvastatin
  • (no location specified)
Nov 16, 2023

Abdominal Aortic Aneurysm Trial (Evolocumab, Placebo)

Not yet recruiting
  • Abdominal Aortic Aneurysm
  • (no location specified)
Oct 12, 2023

Stroke, Acute Ischemic, PCSK9 Inhibitor Trial in Seoul (Alirocumab)

Not yet recruiting
  • Stroke, Acute Ischemic
  • PCSK9 Inhibitor
  • Seoul, Korea, Republic of
    Asan Medical Center
Oct 9, 2023

In-hospital Initiation of PCSK9 Inhibitor in Acute Myocardial

Completed
  • Coronary Disease
  • Evolocumab 140 MG/ML
  • (no location specified)
Jan 7, 2022

Qualitative Features of Atherosclerotic Plaques

Active, not recruiting
  • Atherosclerotic Cardiovascular Disease
  • Riga, Latvia
    Pauls Stradins Clinical University Hospital
Dec 5, 2022

Immunomodulatory Effects of PCSK9 Inhibition

Not yet recruiting
  • Atherosclerotic Cardiovascular Disease
  • +3 more
  • Contrast-enhanced CCTA
  • 99mTc-tilmanocept SPECT/CT scanning
  • Boston, Massachusetts
    Massachusetts General Hospital
Jan 30, 2023

PCSK9 Polymorphism and Risk of Cardiac Rupture

Recruiting
  • Post-Infarction Heart Rupture
  • Gene Polymorphism
  • Genetic analysis for PCSK9 polymorphisms
  • Varese, Italy
    Matteo Matteucci
Aug 15, 2022

ASCVD, Atherosclerotic Cardiovascular Disease, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Trial (Evolocumab,

Not yet recruiting
  • ASCVD
  • +3 more
  • (no location specified)
Aug 3, 2023

Intracranial Atherosclerosis, Acute Ischemic Stroke, ICAS - Intracranial Atherosclerosis Trial in Chiayi City (Alirocumab)

Recruiting
  • Intracranial Atherosclerosis
  • +2 more
  • Chiayi City, Taiwan
    Yenchu Huang
Nov 29, 2022

Dyslipidemias, Hyperlipidemias, Liver Transplant Disorder Trial in Moscow (Pitavastatin, PCSK9 inhibitor)

Recruiting
  • Dyslipidemias
  • +5 more
  • Moscow, Russian Federation
    National Medical Research Centre for Therapy and Preventive Medi
Sep 8, 2022

Early PCSK9 Inhibitor on Ventricular Remodling Trial in Shanghai (PCSK9 inhibitor (Alirocumab)plus standard medications,

Recruiting
  • Early PCSK9 Inhibitor on Ventricular Remodling
  • PCSK9 inhibitor （Alirocumab）plus standard medications
  • standard medications
  • Shanghai, Shanghai, China
  • +1 more
May 23, 2022

Adverse Effect of Cardiovascular Medications (Diagnosis) Trial in Zibo (Evolocumab combined with statins, Statin)

Recruiting
  • Adverse Effect of Cardiovascular Medications (Diagnosis)
  • Evolocumab combined with statins
  • Statin
  • Zibo, Shandong, China
    Zibo Central Hospital
Mar 24, 2023

Sars-CoV-2 Infection Trial in Bydgoszcz (Evolocumab, Saline solution)

Completed
  • Sars-CoV-2 Infection
  • Bydgoszcz, Poland
    Antoni Jurasz University Hospital No. 1
Dec 14, 2022

Lipid Metabolism, Cardiovascular Diseases Trial in Shenzhen (PCSK9 inhibitor)

Recruiting
  • Lipid Metabolism
  • Cardiovascular Diseases
  • PCSK9 inhibitor
  • Shenzhen, Guangdong, China
    Tangzhiming Li
May 4, 2022

Atherosclerotic Cardiovascular Disease Trial in Grenoble (Evolocumab 140 MG/ML [Repatha])

Recruiting
  • Atherosclerotic Cardiovascular Disease
  • Evolocumab 140 MG/ML [Repatha]
  • Grenoble, France
    Grenoble University Hospital
May 18, 2022

Acute Coronary Syndrome, Hyperlipidemias, Percutaneous Coronary Intervention Trial in Nanjing (Placebo plus high-intensity

Not yet recruiting
  • Acute Coronary Syndrome
  • +3 more
  • Placebo plus high-intensity statin
  • PCSK 9 Inhibitor plus high-intensity statin
  • Nanjing, Jiangsu, China
    Nanjing First Hospital
Aug 1, 2022